Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;205(11):1677-87.
doi: 10.1093/infdis/jis252. Epub 2012 Apr 5.

Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus

Affiliations

Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus

David R Cameron et al. J Infect Dis. 2012 Jun.

Abstract

The genetic mechanisms that contribute to reduced susceptibility to vancomycin in Staphylococcus aureus are complex and heterogeneous. In addition, debate is emerging as to the true effect of reduced susceptibility to vancomycin on staphylococcal virulence. To investigate this, comparative genomics was performed on a collection of vancomycin-exposed isogenic S. aureus pairs (14 strains in total). Previously described mutations were observed in genes such as vraG, agrA, yvqF, and rpoB; however, a new mechanism was identified involving a serine/threonine phosphatase, Stp1. After constructing an stp1 deletion mutant, we showed that stp1 is important in vancomycin susceptibility and cell wall biosynthesis. Gene expression studies showed that stp1 also regulates virulence genes, including a hemolysin, superantigen-like protein, and phenol-soluble modulin, and that the deletion mutant is attenuated in virulence in vivo. Stp1 provides a new link between vancomycin susceptibility and virulence in S. aureus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Deletion of stp1 results in reduced vancomycin susceptibility in Staphylococcus aureus. (A) Vancomycin minimum inhibitory concentrations (MICs) were determined by Etest for A5937, A5937Δstp1, the complemented strain A5937Δstp1-C, and the vancomycin nonsusceptible isolate A5940. Values in parentheses represent MICs based on broth dilution. (B) Determination of vancomycin heteroresistance was performed using population analysis profiling. The stp1 deletion mutant had subpopulations that grew in the nonsusceptible range (>2 µg/mL); this was not seen in the parent strain (A5937) but was more pronounced in the clinical vancomycin-intermediate S. aureus daughter strain (A5940). CFU, colony-forming unit. (C) Transmission electron microscopy was performed to determine cell wall thickness. Three representative cells from each strain are shown, and values represent mean cell wall thickness (95% confidence interval). A5940 had the thickest cell wall, followed by the A5937Δstp1 and finally A5937.
Figure 2.
Figure 2.
Deletion of stp1 results in attenuated virulence in Staphylococcus aureus. (A) Six-week-old C57BL/6J mice were injected with ∼1.0 × 108 bacterial cells. Kaplan-Meier curves indicate time to euthanasia for each strain. A5937 produced significantly more killing compared with both A5937Δstp1 and A5940 (P = .01; log-rank test). (B) Macroscopic and (C) histopathological analyses showed that the clinical vancomycin-susceptible parent strain (A5937) caused hepatic abscess formation and tissue necrosis, whereas this was not seen with the stp1 deletion mutant (A5937Δstp1) and the clinical vancomycin-intermediate S. aureus daughter strain (A5940). White arrows point to abscess formation in the liver; N represents severe necrosis; and I represents inflammatory infiltrate. Tissues were stained with hematoxylin and eosin.

Comment in

References

    1. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670–3. - PubMed
    1. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–7. - PubMed
    1. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448–51. - PubMed
    1. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521–8. - PubMed
    1. Howden BP, Johnson PD, Charles PG, Grayson ML. Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2004;39:1544. reply 1544–5. - PubMed

Publication types

MeSH terms